Progyny, Inc.
PGNY Nasdaq· Services-Misc Health & Allied Services, Nec
Last close · Oct 23, 2026
$28.97
KIRA · Stoqly’s AI analyst, in plain words
- Progyny, Inc. had $1.3B of revenue in fiscal 2025, up 10.4% on the year before. Over five years, revenue changed +30.2% a year on average.
- Its operating margin was 6.6%, up 0.8 pts: of every 100 in sales, about 7 is left after running the business.
- Progyny, Inc. made $58.5M of net profit in fiscal 2025.
- Free cash flow was $192M in fiscal 2025, 14.9% of revenue.
- Progyny, Inc. returned $81.7M to shareholders in fiscal 2025, 43% of free cash flow. The diluted share count fell 5.9%.
Market cap
$2.4B
P/E
31.5x
Revenue
$1.3B
Net income
$58.5M
Free cash flow
$192M
Operating margin
6.6%
Progyny, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+10.4%
Yes. Sales grew 10.4% last year.
Does it make a profit?
4.5%
A little. It keeps 4.5% of every sale as profit.
Does profit turn into cash?
14.9%
Yes. 14.9% of sales ends up as free cash.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
31.5x
One share costs 31.5 times its yearly profit per share.
What Progyny, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- Progyny, Inc.
- CIK
- 0001551306
Progyny, Inc. · PGNY
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $501M | $787M | $1.1B | $1.2B | $1.3B |
| Revenue growth | 45.2% | 57.2% | 38.3% | 7.2% | 10.4% |
| Net interest income | $0.5M | $0.8M | $3.3M | — | — |
| Gross margin | 22.4% | 21.3% | 21.9% | 21.7% | 23.6% |
| Operating margin | 6.5% | 3.0% | 5.7% | 5.8% | 6.6% |
| Net income | $65.8M | $30.4M | $62.0M | $54.3M | $58.5M |
| Net margin | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% |
| Diluted EPS | $0.66 | $0.30 | $0.62 | $0.57 | $0.65 |
| Cash | |||||
| Cash from operations | $26.0M | $80.4M | $189M | $179M | $210M |
| Capital expenditure | $2.1M | $3.2M | $3.6M | $5.4M | $18.4M |
| Free cash flow | $23.9M | $77.2M | $185M | $174M | $192M |
| FCF margin | 4.8% | 9.8% | 17.0% | 14.9% | 14.9% |
| Share buybacks | — | $0.0M | $0.0M | $300M | $81.7M |
| Share count change | 1.3% | −0.4% | 0.7% | −5.2% | −5.9% |
| Debt and strength | |||||
| Cash and short-term investments | $119M | $189M | $371M | $228M | $310M |
| Shareholders' equity | $252M | $377M | $553M | $422M | $516M |
| Current ratio | 2.6x | 2.7x | 3.4x | 2.8x | 2.7x |
| Returns and quality | |||||
| Return on equity | 31.4% | 9.7% | 13.3% | 11.1% | 12.5% |
| Return on tangible equity | 27.5% | 8.3% | 11.5% | 13.4% | 11.9% |
| Piotroski F-score | 6 | 6 | 6 | 6 | 5 |
| Altman Z'' | 6.0 | 6.2 | 7.7 | 7.2 | 7.1 |
Insiders bought, 12 months
$1.9M
1 insider
Insiders sold, 12 months
$2.3M
6 insiders
Of sales under plans
70%
$1.6M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Progyny, Inc. · PGNY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $28.97 a share, the company is worth $2.4B: 31.5 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001551306). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.